Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
Related Questions
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Would you offer adjuvant radiation therapy for a completely resected, node positive mucoepidermoid carcinoma of the lung?
Would you offer SBRT for a lung lesion adjacent to the heart in a patient receiving bevacizumab?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
What constraints do you use for the BID small cell lung cancer regimen?
How would you post-operatively manage a peripheral stage I small cell lung carcinoma s/p upfront wedge resection with an R1 microscopic positive margin along the staple line and visceral pleural invasion?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
